新动态

未来25年美国糖尿病患者数量将翻番 一项发表于《糖尿病护理》杂志的研究论文表明，到2034年，美国糖尿病的人数将会翻番，和糖尿病有关的花费也将增加两倍，达到创记录的3360亿美元。     

新动态

可减少服药次数的新制剂即将上市；美国研究发现哺乳可降低母亲患糖尿病风险；补充维生素和矿物质可改善糖尿病患者的肾功能。     

新动态

减肥手术有助于治疗糖尿病；2型糖尿病呈增龄性上升趋势     

新动态

FDA限制文迪雅使用范围 FDA（美国食品和药物管理局）日前宣布，由葛兰素史克公司生产的糖尿病药物文迪雅，今后将只能适用于两他药物控制血糖的2型糖尿病患者，另一类是目前正在使用文迪雅目效果良好的患者。     

新动态

非动脉瘤性SAH与1型糖尿病 芬兰的一项研究表明,非动脉瘤性蛛网膜下腔出血或许应算作1型糖尿病的一个独特的微血管并发症。     

新动态

新研究提示：出现蛋白尿疑预示认知功能下降 很多糖尿病患者都知道，尿液中出现蛋白很可能预示着发生了糖尿病。肾病的并发症，而据国外一项最新研究结果表明，糖尿病患者若出现蛋白尿，还有可能预示着认知功能的下降，主要影响患者大脑对信息处理的速度。     

新动态

糖尿病规范注射日 调查显示,我国九成多糖尿病患者注射胰岛素不规范,普遍存在着三大问题：一是患者随意调整胰岛素剂量,导致血糖波动较大;二是一次性针头多次重复使用,     

新动态

他喷他多将可用于缓解糖尿病性疼痛 他喷他多是一种长效口服阿片类药物，现在经美国食品和药物管理局（FDA）批准，可用于治疗源于糖尿病周围神经病变所引起的疼痛性症状，包括刺麻感、感觉丧失和手臂、腿、手、脚等部位的疼痛。他喷他多专用于患有慢性疼痛性疾病，24小时连续不断地需要止疼药的人们，一天服两次即可。作为一种阿片样药物，他喷他多可导致成瘾性，最常见的副作用是恶心、眩晕、呕吐、困倦和头痛。     

新动态

最新统计显示：全球每21秒就有1人死于脑中风；芙蓉菊可能成力防治糖尿病的新型植物药；中药治疗磺脲类药继发性失效；糖尿病新药给1型糖尿病患者带来曙光；韩国科学家培育成功胰岛素分泌细胞；“强化控制血糖达标”全球项目在中国启动；     

新动态

糖尿病是一种“数字病” “糖尿病是一种‘数字病’，因为它在发病前期基本没有明显症状，容易被人忽视。如果不高度重视，其后果非常可怕”，北京大学人民医院内分泌科主任纪立农教授表示。     

新动态

文迪雅再度成焦点；糖尿病足有望摆脱截肢厄运；迎接2008年世界糖尿病日     

New anti-HIV drugs in development

Several new anti-HIV drugs have received Food and Drug Administration (FDA) approval in the past three years, following a period of intense research in the mid-1990s. That cycle of research and development appears to have shifted, with only one drug expected to receive approval in the coming months. That drug, adefovir dipivoxil (Preveon) is Gilead Science's nucleotide analog. Other compounds are early in the development cycle. Those new compounds, which represent all three current anti-HIV drug classes, are summarized, and results presented at medical conferences during the past year are detailed. Several other drugs in development are aiming at novel targets. One new class of drugs is the fusion inhibitors.     

抗血小板治疗新进展

众所周知,血小板在动脉系统血栓形成中起着关键作用,抗血小板治疗已成为预防和治疗动脉系统血栓的基石。目前临床主要应用的抗血小板药物有阿司匹林、二磷酸腺苷（ADP）受体拮抗剂及Ⅱb／Ⅲa受体拮抗剂,在传统抗血小板药物的基础上,新的药物也在不断研发。但是,抗血小板治疗现状仍不理想,在临床抗血小板获益的同时,其局限性及治疗的特异性还存在诸多问题。本文拟以此为中心,结合抗血小板治疗的最新进展进行相关讨论。     

New targets for drug development in asthma

Asthma is a chronic inflammatory disease that affects about 300 million people worldwide, a total that is expected to rise to about 400 million over the next 15-20 years. Most asthmatic individuals respond well to the currently available treatments of inhaled corticosteroids and beta-adrenergic agonists; however, 5-10% have severe disease that responds poorly. Improved knowledge of asthma mechanisms has led to the recognition of different asthma phenotypes that might reflect distinct types of inflammation, explaining the effectiveness of anti-leucotrienes and the anti-IgE monoclonal antibody omalizumab in some patients. However, more knowledge of the inflammatory mechanisms within the airways is required. Improvements in available therapies-such as the development of fast-onset, once-a-day combination drugs with better safety profiles-will occur. Other drugs, such as inhaled p38 MAPK inhibitors and anti-oxidants, that target specific pathways or mediators could prove useful as monotherapies, but could also, in combination with corticosteroids, reduce the corticosteroid insensitivity often seen in severe asthma. Biological agents directed against the interleukin-13 pathway and new immunoregulatory agents that modulate functions of T-regulatory and T-helper-17 cells are likely to be successful. Patient-specific treatments will depend on the development of discriminatory handprints of distinct asthma subtypes and are probably over the horizon. Although a cure is unlikely to be developed in the near future, a greater understanding of disease mechanisms could bring such a situation nearer to reality.